Comparing of Aclaris Therapeutics Inc. (ACRS) and Chiasma Inc. (NASDAQ:CHMA)

As Biotechnology companies, Aclaris Therapeutics Inc. (NASDAQ:ACRS) and Chiasma Inc. (NASDAQ:CHMA) are our subject to contrast. And more specifically their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aclaris Therapeutics Inc. 10.09M 23.72 132.74M -3.85 0.00
Chiasma Inc. N/A 0.00 31.26M -1.16 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Aclaris Therapeutics Inc. and Chiasma Inc.


Table 2 has Aclaris Therapeutics Inc. and Chiasma Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Aclaris Therapeutics Inc. -1,315.56% -62.8% -55.6%
Chiasma Inc. 0.00% -56.3% -48.6%

Risk and Volatility

Aclaris Therapeutics Inc. is 22.00% more volatile than Standard and Poor’s 500 due to its 1.22 beta. Chiasma Inc.’s 42.00% more volatile than Standard and Poor’s 500 volatility due to the company’s 1.42 beta.


The Current Ratio and Quick Ratio of Aclaris Therapeutics Inc. are 6.5 and 6.5 respectively. Its competitor Chiasma Inc.’s Current Ratio is 5.6 and its Quick Ratio is 5.6. Aclaris Therapeutics Inc. can pay off short and long-term obligations better than Chiasma Inc.

Analyst Recommendations

Aclaris Therapeutics Inc. and Chiasma Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aclaris Therapeutics Inc. 0 0 0 0.00
Chiasma Inc. 0 0 2 3.00

Competitively the average price target of Chiasma Inc. is $13.5, which is potential 131.96% upside.

Institutional & Insider Ownership

Aclaris Therapeutics Inc. and Chiasma Inc. has shares held by institutional investors as follows: 96.8% and 70.6%. 4.3% are Aclaris Therapeutics Inc.’s share held by insiders. Competitively, Chiasma Inc. has 0.3% of it’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aclaris Therapeutics Inc. 3.65% -2.3% -21.72% -56.54% -65.15% -7.85%
Chiasma Inc. 18.45% 35.71% 19.35% 97.92% 206.45% 52.73%

For the past year Aclaris Therapeutics Inc. has -7.85% weaker performance while Chiasma Inc. has 52.73% stronger performance.


On 7 of the 10 factors Chiasma Inc. beats Aclaris Therapeutics Inc.

Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. Its lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101 as a prescription treatment for common warts. In addition, it is developing JAK inhibitors, including ATI-50001 that has completed Phase I clinical trial for the oral treatment of alopecia totalis and alopecia universalis; and ATI-50002, which has completed Phase I clinical trial for the topical treatment of patchy autoimmune dermatologic condition. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Malvern, Pennsylvania.

Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies using transient permeability enhancer technology platform. The company offers octreotide capsules, which is in Phase III clinical trial for the treatment of acromegaly, a condition that results in the bodyÂ’s production of excess growth hormone under the MYCAPSSA name. Chiasma, Inc. was founded in 2001 and is headquartered in Newton, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.